Annals On Call Podcast
Checkpoint Inhibitors: What Generalists Need to Know
Apr 15, 2024
Drs. Reaford Blackburn Jr. and Brian C. Westbrook discuss immune-related adverse events from checkpoint inhibitors, highlighting the mechanisms of action, management of adverse events, patient response variations, and the importance of early recognition by healthcare providers.
22:39
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Checkpoint inhibitors enhance the immune response against cancer by suppressing immune checkpoints like CTLA4 and PD1.
- Immune-related adverse events from checkpoint inhibitors, such as colitis and myocarditis, require prompt recognition and management.
Deep dives
Understanding Checkpoint Inhibitors in Oncology
Checkpoint inhibitors target immune checkpoints, allowing the immune system to attack cancer cells that evade detection. These inhibitors, such as CTLA4 and PD1, aim to enhance the immune response against cancer. The adaptation of cancer cells to over-express these proteins can hinder the immune system's recognition of cancer as a threat. By suppressing these checkpoints, checkpoint inhibitors help unleash the immune system against cancer, albeit with the potential for adverse effects on normal cells.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
